Alvotech has announced the filing of its AVT02 higher-strength adalimumab version of Humira 100mg/ml with both the FDA and the EMA, as well as disclosing expected decision dates. Teva will market the biosimilar in the US and Stada in Europe.

After an eventful year for the off-patent industry, the world’s leading generics and biosimilars players have switched places in Generics Bulletin’s newly compiled global sales ranking.

Germany's Stada has expanded its deal with Enymatica to take the latter's ViruProtect common cold brand into Russia, the CIS and beyond.

Consumer health companies are starting to step into the lucrative but fast-changing and complex EU cannabidiol market. But what are the key considerations for firms before making such a move, or if they have already? HBW Insight speaks to CBD regulatory expert Greer Deal.